Literature DB >> 14638958

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

W T Mayr1, S J Pittock, R L McClelland, N W Jorgensen, J H Noseworthy, M Rodriguez.   

Abstract

BACKGROUND: Epidemiologic data for multiple sclerosis (MS) in Olmsted County, MN, have been recorded for almost 100 years and have indicated that the increasing prevalence rate was likely due in part to an increasing incidence rate.
METHODS: All cases of MS diagnosed from 1985 to 2000 were identified using the centralized diagnostic index at the Mayo Clinic and the Rochester Epidemiology Program Project, a shared database of all medical practitioners in the county. Patients were required to have established residency at least 1 year prior to diagnosis of MS. Results were also age- and sex-adjusted to control for shifts in the population structure.
RESULTS: The raw prevalence of MS was determined to be 177 per 100,000 on December 1, 2000, and the raw incidence rate was 7.5 per 100,000 person-years at risk from 1985 to 2000.
CONCLUSIONS: After age and sex adjustment to a common population, these prevalence and incidence rates of MS appear to have been stable rather than increasing over the past 20 years.

Entities:  

Mesh:

Year:  2003        PMID: 14638958     DOI: 10.1212/01.wnl.0000094316.90240.eb

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  60 in total

Review 1.  The 'hygiene hypothesis' for autoimmune and allergic diseases: an update.

Authors:  H Okada; C Kuhn; H Feillet; J-F Bach
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

2.  [MS registry in Germany--design and first results of the pilot phase].

Authors:  P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 3.  Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Authors:  Michael J Thorpy
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

5.  Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease.

Authors:  S J Pittock; R L McClelland; S J Achenbach; F Konig; A Bitsch; W Brück; H Lassmann; J E Parisi; B W Scheithauer; M Rodriguez; B G Weinshenker; C F Lucchinetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

6.  Physical activity and self-reported cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-sectional analysis.

Authors:  Robert W Motl; Bo Fernhall; Edward McAuley; Gary Cutter
Journal:  Neuroepidemiology       Date:  2011-05-20       Impact factor: 3.282

7.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

Review 9.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

10.  Preliminary studies on the clinical features of multiple sclerosis in Korea.

Authors:  Sang-Soo Lee; Eun-Hee Sohn; Seon-Woo Nam
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.